Next Article in Journal
Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer
Next Article in Special Issue
BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas
Previous Article in Journal
Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma
Previous Article in Special Issue
Precision Medicine Management of Chronic Lymphocytic Leukemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 12
Issue 4
10.3390/cancers12040884
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas

by
Ivonne Vazquez
1,
Natalia Papaleo
1,
Eugenia Garcia
2,
Marta Salido
1,
Antonio Salar
3,
Silvia Hernandez
4,
Xavier Calvo
1 and
Luis Colomo
1,4,*
1
Department of Pathology, Hematopathology Section, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain
2
Department of Pathology-IdiPAZ, Hospital Universitario La Paz, 28046 Madrid, Spain
3
Department of Hematology, Hospital del Mar, Institute of Investigacions Mediques-IMIM, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain
4
Department of Health and Experimental Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 884; https://doi.org/10.3390/cancers12040884
Submission received: 1 March 2020 / Revised: 3 April 2020 / Accepted: 4 April 2020 / Published: 5 April 2020
(This article belongs to the Special Issue Recent Advances in the Pathogenesis of B Cell Malignancies)
Browse Figures
Versions Notes

Abstract

MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas.
Keywords: MYC rearrangement; LMO2; large B-cell lymphoma; immunohistochemistry MYC rearrangement; LMO2; large B-cell lymphoma; immunohistochemistry

Share and Cite

MDPI and ACS Style

Vazquez, I.; Papaleo, N.; Garcia, E.; Salido, M.; Salar, A.; Hernandez, S.; Calvo, X.; Colomo, L. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Cancers 2020, 12, 884. https://doi.org/10.3390/cancers12040884

AMA Style

Vazquez I, Papaleo N, Garcia E, Salido M, Salar A, Hernandez S, Calvo X, Colomo L. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Cancers. 2020; 12(4):884. https://doi.org/10.3390/cancers12040884

Chicago/Turabian Style

Vazquez, Ivonne, Natalia Papaleo, Eugenia Garcia, Marta Salido, Antonio Salar, Silvia Hernandez, Xavier Calvo, and Luis Colomo. 2020. "Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas" Cancers 12, no. 4: 884. https://doi.org/10.3390/cancers12040884

APA Style

Vazquez, I., Papaleo, N., Garcia, E., Salido, M., Salar, A., Hernandez, S., Calvo, X., & Colomo, L. (2020). Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Cancers, 12(4), 884. https://doi.org/10.3390/cancers12040884

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop